C1 inhibitor mets endpoints
In a Phase III study, Pharming Group N.V.’s (Leiden) recombinant human C1 inhibitor Rhucin® met the primary and secondary endpoints of safety and efficacy as acute treatment for hereditary angioedema (HAE). Patients who received the 100 U/kg dose of Rhucin® reported median first symptom relief at 68 minutes, while those that received the 50 U/kg dose reported relief at 100 minutes. Patients that received placebo reported symptom relief only at 258 minutes. The time to minimal clinical symptoms – the secondary endpoint – was reported by patients in the 100 U/kg, 50 U/kg, and placebo groups as 245, 247, and 1098 minutes respectively. There was no statistically significant difference observed between patients treated with the 100 U/kg and the 50 U/kg dose of Rhucin®.